Lee, Jae-Bok; Woo, Ok Hee; Park, Kyong Hwa; Woo, Sang Uk; Yang, Dae Sik; Kim, Ae-Ree; Lee, Eun Sook; Kim, Yeul Hong; Kim, Jun Suk; Seo, Jae Hong
Investigational new drugs
2011Feb ; 29 ( 1 ) :182-8.
PMID : 19756376
ÀúÀÚ »ó¼¼Á¤º¸
Lee, Jae-Bok -
Woo, Ok Hee -
Park, Kyong Hwa -
Woo, Sang Uk -
Yang, Dae Sik -
Kim, Ae-Ree -
Lee, Eun Sook -
Kim, Yeul Hong -
Kim, Jun Suk -
Seo, Jae Hong -
ABSTRACT
Although various new agents have been developed for the treatment of patients with metastatic breast cancer (MBC), overall survival rates have changed little in the last half century. We conducted meta-analysis to verify the clinical efficacy of bevacizumab for the salvage treatment of MBC. Event-based hazard ratios (HR) with 95% confidence intervals (95% CIs) were derived, and a test of heterogeneity was applied. Four studies, with a total of 2,860 patients, met the inclusion criteria for analysis. The pooled results of clinical efficacies were: HR for progression free survival 0.69 (95% CI, 0.58-0.81, z?=?4.54, P?<0.001); HR for overall survival 0.92 (95% CI, 0.82-1.03, z?=1.44, P?=?0.15); and HR for the clinical objective response rate 1.53 (95% CI, 1.37-1.71, z?=?7.37, P?
Bevacizumab Metastatic breast cancer Meta-analysis Salvage treatment
MESH
Antibodies, Monoclonal/adverse effects/*therapeutic use, Antibodies, Monoclonal, Humanized, Bevacizumab, Breast Neoplasms/*drug therapy/*pathology, Female, Humans, Neoplasm Metastasis, Publication Bias, *Randomized Controlled Trials as Topic, *Salvage Therapy
¸µÅ©